Log in

Tricida Stock Forecast, Price & News

-0.28 (-3.00 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $9.05
50-Day Range
MA: $12.10
52-Week Range
Now: $9.05
Volume1.18 million shs
Average Volume526,582 shs
Market Capitalization$452.94 million
P/E RatioN/A
Dividend YieldN/A
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More
Tricida logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TCDA



Sales & Book Value

Annual SalesN/A
Book Value$5.32 per share


Net Income$-176,810,000.00


Market Cap$452.94 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
-0.28 (-3.00 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Tricida (NASDAQ:TCDA) Frequently Asked Questions

How has Tricida's stock been impacted by COVID-19?

Tricida's stock was trading at $28.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 67.7% and is now trading at $9.05.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Tricida?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tricida

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Tricida

How were Tricida's earnings last quarter?

Tricida Inc (NASDAQ:TCDA) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.46) by $0.30.
View Tricida's earnings history

What price target have analysts set for TCDA?

3 brokerages have issued twelve-month price objectives for Tricida's shares. Their forecasts range from $10.00 to $40.00. On average, they expect Tricida's share price to reach $23.33 in the next year. This suggests a possible upside of 157.8% from the stock's current price.
View analysts' price targets for Tricida

Who are some of Tricida's key competitors?

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Aphria (APHA), BioMarin Pharmaceutical (BMRN), CVS Health (CVS), General Motors (GM), Moderna (MRNA), Sorrento Therapeutics (SRNE) and AbbVie (ABBV).

Who are Tricida's key executives?

Tricida's management team includes the following people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
  • Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
  • Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
  • Steffen Pietzke, VP of Fin. & Chief Accounting Officer
  • Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.24%), Cormorant Asset Management LP (1.74%), Point72 Asset Management L.P. (1.30%), Federated Hermes Inc. (0.76%), Artal Group S.A. (0.57%) and Opaleye Management Inc. (0.48%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida

Which institutional investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Artal Group S.A., Engineers Gate Manager LP, Goldman Sachs Group Inc., California Public Employees Retirement System, Cormorant Asset Management LP, PDT Partners LLC, and Bank of America Corp DE. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl.
View insider buying and selling activity for Tricida

Which institutional investors are buying Tricida stock?

TCDA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Vanguard Group Inc., Jacobs Levy Equity Management Inc., New York State Common Retirement Fund, Federated Hermes Inc., Alyeska Investment Group L.P., Tekla Capital Management LLC, and Opaleye Management Inc.. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $9.05.

How big of a company is Tricida?

Tricida has a market capitalization of $452.94 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.